Novo Nordisk A/S (NVO) 20-F2012 FY Annual report (foreign)

Filed: 6 Feb 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: austerity, Australia, Benchmark, bought, cardiovascular, Circuit, commence, constant, cooperation, coverage, device, DNA, fluctuate, HR, IDegLira, identical, internationally, Kaluga, laboratory, land, lease, Manhattan, mindset, narrative, NNIT, pending, previously, ready, ref, Revisionspartnerselskab, Sanofi, stayed, Supreme, temperature, trend, Union, varying, vesting

Removed: accelerated, Additionally, assisting, auditing, celebrated, certified, check, checked, clear, comparative, consisting, covering, dealt, Eli, file, filer, fill, formulate, GAAP, goal, groundbreaking, handling, hiring, ISO, mark, mind, NovoMix, NovoRapid, Occupational, preceding, prepare, processing, proper, pursue, rDNA, responded, responding, Revisionsaktieselskab, ROIC, seasoned, setting, shell, shorter, trade, visit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NVO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.3

Consent of independent registered public accounting firm

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-82318 and No. 333-83724) of Novo Nordisk A/S of our report dated 1 February 2012 relating to the Consolidated Financial Statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.

/s/ PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Copenhagen, Denmark
8 February 2012